Promacta (eltrombopag) - Novartis
Human bioequivalence study of eltrombopag ethanolamine dry suspension (chinadrugtrials.org.cn) - Oct 7, 2026 - P=N/A | N=34 | Sponsor: Shandong Langnuo Pharmaceutical Co., Ltd. 
New trial • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Hematological Disorders • Hepatitis C • Immune Thrombocytopenic Purpura • Infectious Disease • Inflammation • Thrombocytopenia • Thrombocytopenic Purpura • Transplantation
https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=a6177184c349427e9083e47685d1f9c8
 
Oct 7, 2026
 
Prev Next